| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Email: |
doncunbiosci@gmail.com |
| Products Intro: |
Product Name:VT-1598
Purity:98% HPLC Package:100mg；250mg；1g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:VT-1598
CAS:2089320-99-8
Package:2mg/RMB 2650;25mg/RMB 12200;50mg/RMB 15900
|
| Company Name: |
Suzhou Haiben Pharmaceutical Co., Ltd
|
| Tel: |
19353112242 |
| Email: |
1816280386@qq.com |
| Products Intro: |
Product Name:VT-1598
CAS:2089320-99-8
Purity:98% HPLC Package:10g;100g;1kg;10kg
|
VT-1598 manufacturers
- VT-1598
-
- $2650.00 / 100mg
-
2025-10-27
- CAS:2089320-99-8
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | VT-1598 Basic information |
| Product Name: | VT-1598 | | Synonyms: | VT-1598;Benzonitrile, 4-[[4-[2-[6-[(2R)-2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-3-pyridinyl]ethynyl]phenoxy]methyl]- | | CAS: | 2089320-99-8 | | MF: | C31H20F4N6O2 | | MW: | 584.52 | | EINECS: | | | Product Categories: | | | Mol File: | 2089320-99-8.mol |  |
| | VT-1598 Chemical Properties |
| form | Solid | | color | Off-white to light yellow |
| | VT-1598 Usage And Synthesis |
| Uses | VT-1598 is an orally active and selective fungal inhibitor targeting CYP51. VT-1598 shows anti-fungal activity against Candida auris[1][2]. VT-1598 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | | in vivo | VT-1598 (oral gavage; 5, 15, and 50?mg/kg; once daily; 7 d) treatment shows a significant and dose-dependent survival advantage, and dose-dependent reductions in fungal burden[1].
VT-1598 (oral gavage; 3.2, 8, and 20?mg/kg; once daily; 4 d) is present to a great extent in the plasma and tongue after oral administration in Act1-deficient mice infected with C. albicans[2]. | Animal Model: | Mice model of invasive candidiasis[1] | | Dosage: | 5, 15, and 50?mg/kg | | Administration: | Oral gavage; once daily; 7 days | | Result: | Observed median survival in the VT-1598 15 mg/kg and 50 mg/kg groups (15?days and >21?days, respectively) longer than the control group.
Observed kidney fungal burden in mice treated with 15 mg/kg and 50 mg/kg doses (mean log10 CFU/g, 5.40 and 3.67, respectively) lower than the vehicle control group.
Showed mean trough concentrations 1.55?μg/mL after 7?days of therapy in the 5 mg/kg group, 6.78?μg/mL in the 15 mg/kg group, and 14.2?μg/mL in the 50 mg/kg group.
|
| Animal Model: | Act1-deficient mice infected with C. albicans[2] | | Dosage: | 3.2, 8, and 20?mg/kg | | Administration: | Oral gavage; once daily; 4 days | | Result: | Resulted in high concentrations in the plasma and tongues of Candida-infected mice. |
| | References | [1] Nathan P Wiederhold, et al. The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris. Antimicrob Agents Chemother. 2019 Feb 26;63(3):e02233-18. DOI:10.1128/AAC.02233-18
[2] Timothy J Break, et al. VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice. J Antimicrob Chemother. 2018 Aug 1;73(8):2089-2094. DOI:10.1093/jac/dky170 |
| | VT-1598 Preparation Products And Raw materials |
|